KYinno

KYinno Biotechnology is a preclinical contract research organization (CRO) based in Beijing, China, specializing in oncology research and development. It offers customized services for drug discovery, encompassing both in vitro and in vivo studies specifically focused on cancer treatments. The company supports pharmaceutical and biotechnology firms by leveraging its specialized research platforms and collaborative capabilities, primarily serving the oncology and cancer treatment research sectors. With approximately 130 employees, KYinno has secured a total of $23.49 million in funding to date. Its most recent capital raise, a Series A-II round, brought in $15.66 million approximately four years ago. The organization was established in 2017; founder names are not publicly disclosed. Its business model centers on operates as a CRO offering paid research services for drug R&D to pharmaceutical and biotechnology companies.